Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accorda ... in Germany

Work Detail

Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V From January 1, 2027. Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Betamethasone In The Dosage Forms Cre, Emu, Sal And Loe,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Combination Captopril + Hydrochlorothiazide,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Colistin Or Colistin Methate Sodium In Selected Dosage Forms,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Dorzolamide In A Multi-Dose Container (Mdo),Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Everolimus In The Dosage Form Tab,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Combination Formoterol + Aclidinium Bromide,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Formoterol In Selected Potencies,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Lapatinib,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Linezolid In The Dosage Form Inf,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V With The Active Ingredient Loratadine,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Macrogol 3350 In The Dosage Form Ple And In Certain Potencies,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Mometasone In The Dosage Form Loe,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Octreotide In The Dosage Forms Fer, Ilo, Iil,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Olopatadine,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Oxazepam,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Oxybutynin In The Dosage Form Liv,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Progesterone In The Dosage Form Vka,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Roflumilast With An Effective Strength Of 0.25 Mg,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tamoxifen,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Terazosin,Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Triacylglycerol Lipase With A Potency Of 40,000 Pheur-E.,Conclusion Of Non-Exclusive

Contact Information